Liposomes Targeting P21 Activated Kinase-1 (PAK-1) and Selective for Secretory Phospholipase A2 (sPLA2) Decrease Cell Viability and Induce Apoptosis in Metastatic Triple-Negative Breast Cancer Cells
Authors: Nhat D Quach
Brian S Cummings
Payaningal R Somanath
Wided Najahi-Missaoui
Journal: International Journal of Molecular Sciences (2020)
Discipline: CHEMISTRY
Keywords: SPRL-IPA-3; SSL-IPA-3; cell death; cell toxicity; triple-negative breast cancer.
Affiliations: Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA 30602, USA., Department of Molecular Pharmacology, Physiology & Biotechnology, Brown University, Providence, RI 02906, USA., Clinical and Experimental Therapeutics, University of Georgia and Charlie Norwood VA Medical Center, Augusta, GA 30912, USA., Department of Medicine and Cancer Center, Augusta University, Augusta, GA 30912, USA., Interdisciplinary Toxicology Program, University of Georgia, Athens, GA 30602, USA.

Abstract:  P21 activated kinases (or group I PAKs) are serine/threonine kinases whose expression is altered in prostate and breast cancers. PAK-1 activity is inhibited by the small molecule "Inhibitor targeting PAK-1 activation-3" (IPA-3), which has selectivity for PAK-1 but is metabolically unstable. Secretory Group IIA phospholipase A2 (sPLA2) expression correlates to increased metastasis and decreased survival in many cancers. We previously designed novel liposomal formulations targeting both PAK-1 and sPLA2, called Secretory Phospholipase Responsive liposomes or SPRL-IPA-3, and demonstrated their ability to alter prostate cancer growth. The efficacy of SPRL against other types of cancers is not well understood. We addressed this limitation by determining the ability of SPRL to induce cell death in a diverse panel of cells representing different stages of breast cancer, including the invasive but non-metastatic MCF-7 cells, and metastatic triple-negative breast cancer (TNBC) cells such as MDA-MB-231, MDA-MB-468, and MDA-MB-435. We investigated the role of sPLA2 in the disposition of these liposomes by comparing the efficacy of SPRL-IPA-3 to IPA-3 encapsulated in sterically stabilized liposomes (SSL-IPA-3), a formulation shown to be less sensitive to sPLA2. Both SSL-IPA-3 and SPRL-IPA-3 induced time- and dose-dependent decreases in MTT staining in all cell lines tested, but SPRL-IPA-3-induced effects in metastatic TNBC cell lines were superior over SSL-IPA-3. The reduction in MTT staining induced by SPRL-IPA-3 correlated to the expression of Group IIA sPLA2. sPLA2 expression also correlated to increased induction of apoptosis in TNBC cell lines by SPRL-IPA-3. These data suggest that SPRL-IPA-3 is selective for metastatic TNBC cells and that the efficacy of SPRL-IPA-3 is mediated, in part, by the expression of Group IIA sPLA2. 

Retracted: No

PubPeer comments:
 Page 5, results and discussion: u201cThe result of the binding energy from the docking analysis of bioactive alkaloids (62) and terpenoids (100) to 3-Chymotrypsin-like protease (3CLpro) of the novel SARS-CoV-2 is represented in (supplementary material).u201d The website does not appear to have any supplementary material: https: www.tandfonline.com doi full 10.1080 07391102.2020.1764868 ,